Eisenmenger Complex Management Market is expected to reach valuation of US$ 12.9 Billion by 2033

The global Eisenmenger Complex Management Market is expected to surpass an impressive valuation of US$ 7.7 billion in 2023 and is projected to reach US$ 12.9 billion by 2033, growing at a CAGR of 5.3%.

Generally, the treatment includes relieving the symptoms and associated co-morbidities. Medications such as calcium channel blockers, antiarrhythmic agents, and blood thinning agents are prescribed by the physician. The rising prevalence of Eisenmenger syndrome, government support for the development of orphan drugs, and the growing geriatric population are the main factors that are fuelling growth of the Eisenmenger syndrome treatment market.

Growing expiration of patents presents opportunities that can be leveraged to offer generics at affordable costs which will aid in market expansion. The demand and consumption of generics are expected to rise significantly driven by research and development initiatives and regulatory approvals in developed and developing markets. Thus, fuelling market growth.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16451

Increasing government support to create orphan drugs and surging cases of COVID-19 across the world are anticipated to drive sales in the global market. Apart from this, the presence of a vast population above the age of 60 years with lower immunity level who are often more prone to Eisenmenger syndrome and other related diseases, might propel demand for effective treatment. Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also expected to assist in market expansion.

On the other hand, robust drug pipeline and new product combination awaiting approval or launch are expected to heighten the market competitiveness which will directly benefit the targeted market. For instance, In December 2020, Acceleron Pharma received orphan drug designation for Sotatercept from the European Commission and is available for commercial use in the European markets. This will support market expansion in the forthcoming years.

The technological advancements are also continuously focusing upon the identification of new molecular pathways which contributes to the development of better treatments possible during the forecast period. All these factors propel growth of the market. However, patent expiration of drug molecule and side effects associated with the drugs is anticipated to restrain growth of Eisenmenger complex management market in the forecast period.

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16451

Key Takeaways from the Market Study

  • North America is expected to dominate the market of Eisenmenger syndrome with 48.77 market share during the forecast period.
  • The market in South Asia is projected to grow fastest with a CAGR of 5.5% in the forecast period
  • By drug type, endothelin receptor antagonist segment is expected to lead the market with 48.1 % market share in 2023.
  • By distribution channel, hospital pharmacies segment is anticipated to dominate the market with 65% market share by end of the forecast period.

“Robust drug pipeline and new product combination awaiting approval will fuel the targeted market growth”- says an FMI Analyst

Competitive Landscape

The global Eisenmenger syndrome treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer, Inc, Teva Pharmaceutical Industries Ltd, AstraZeneca plc., Novartis AG, Merck and Co., Inc., GlaxoSmithKline plc., Mylan N.V, Bayer AG

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/16451

Some recent developments in this industry are:

  • In July 2022, Cereno Scientific announced that first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1.
  • In June 2022, Gossamer Bio, Inc. declared the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
  • In December 2021, Aerovate Therapeutics, a clinical stage biopharmaceutical company based in United States, started the Phase 2b/3 clinical trial for testing imatinib, its experimental inhaled formulation in people with Eisenmenger syndrome. The trial is set to help the company in achieving the goal of enhancing the lives of patients suffering from rare cardiovascular diseases. This test will evaluate the ability of AV-101 to resist blood flow in the blood vessels of the lungs.
  • In December 2021, Alembic Pharmaceuticals, a multinational pharmaceutical company headquartered in India, bagged approval from the United States Food and Drug Administration (USFDA) for the marketing of Selexipag tablets. These can now be used to treat pulmonary arterial hypertension. The company’s new drug is considered to be the generic equivalent to Uptravi, the Reference Listed Drug (RLD).

Key Segments Profiled in the Eisenmenger Complex Management Industry Survey

By Drug Type:

  • Antiarrhythmic Agents
  • Blood Thinning Agents
  • Endothelin Receptor Antagonist
  • Others

By Diagnosis:

  • Blood tests
  • Electrocardiogram
  • Chest X-ray
  • Echocardiogram
  • CT Scan
  • MRI
  • Cardiac Catheterization

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User:

  • Hospitals & Clinics
  • Laboratories
  • Others
%d bloggers like this: